

# Notice of Allowability

Application No.

10/823,913

Examiner

Christopher RoDee

Applicant(s)

QI ET AL.

Art Unit

1756

## -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to interview of 6 June 2006.
2. ☒ The allowed claim(s) is/are 1-25.
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
  5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
    - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
      - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
    - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

### Attachment(s)

1. ☒ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date 4/14/04
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date 6/6/06.
7. ☒ Examiner's Amendment/Comment
8. ☒ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_.

### EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Eugene Palazzo on 6 June 2006.

The application has been amended as follows:

In ¶ [0001], line 1, after "10/144147" insert – now abandoned --.

In ¶ [0002], line 1, after "10/369816" insert – US Patent 6,913,863 --.

In ¶ [0003], line 1, after "10/369798" insert – US Patent 6,875,548 --.

In ¶ [0004], line 1, after "10/369812" insert – US Patent 6,824,940 --.

In claim 14, line 1, change "claim 13" to – claim 9 --.

In claim 17, last line, insert "and" between the last two formulae and place a period at the end of the claim.

In claim 18, last line, change "number, preferably selected" to – number selected --.

In claim 19, line 7, insert – and – between the last two formulae, and in the last two lines of the claim, replace the comma after "halogen atom" with a period and delete the remainder of the claim after the newly inserted period.

In claim 24, last line, after "wherein" insert – R" represents a divalent linkage organic group, --.

The following is an examiner's statement of reasons for allowance: the prior art of record fails to disclose or suggest a photoconductive member as claimed having the crosslinked siloxane composite containing a caprolactone-siloxane copolymer group as specified in claim 1 or the specific formulae shown in claims 24 and 25. Shida *et al.* in US Patent 6,479,202 discloses a siloxane resin that is crosslinkable and formed from silane compounds with hydrolysable groups as seen in Formulae 1, 2, and 3. A charge transport compound can be reacted with the silane to give the siloxane a charge transport functionality. The resulting resin is used as a surface layer in an imaging member as seen in the Examples. However, this reference does not disclose the composite of the instant claims having the caprolactone-siloxane copolymer group as specified in claim 1 or the specific formulae shown in claims 24 and 25. Tong *et al.* in US Patent Application Publication 2004/0175637 discloses an imaging member having crosslinked siloxane resins with a charge transport moiety but fails to disclose the caprolactone-siloxane copolymer group as specified in claim 1 or the specific formulae shown in claims 24 and 25. Yu *et al.* in US Patent 6,117,603 disclose a polysiloxane liquid with ester groups in the side chain. This liquid is placed in the surface layer of the imaging member (Abstract; Examples) but the reference does not disclose a liquid having a caprolactone-siloxane copolymer group as specified in claim 1 or the specific formulae shown in claims 24 and 25.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Art Unit: 1756

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher RoDee whose telephone number is 571-272-1388. The examiner can normally be reached on most weekdays from 6:00 to 4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Huff can be reached on 571-272-1385. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

cdr  
6 June 2006



CHRISTOPHER RODEE  
PRIMARY EXAMINER